Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT01750918
Title BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | NLD | ITA | GBR | FRA | ESP | BEL

Facility Status City State Zip Country Details
Novartis Investigative Site Scottsdale Arizona 85259 United States Details
Novartis Investigative Site San Francisco California 94115 United States Details
Novartis Investigative Site Boston Massachusetts 02114 United States Details
Novartis Investigative Site Boston Massachusetts 02215 United States Details
Novartis Investigative Site New York New York 10065 United States Details
Novartis Investigative Site Chapel Hill North Carolina 27599 United States Details
Novartis Investigative Site Philadelphia Pennsylvania 19104 United States Details
Novartis Investigative Site Nashville Tennessee 37203 United States Details
Novartis Investigative Site Bruxelles 1200 Belgium Details
Novartis Investigative Site Leuven 3000 Belgium Details
Novartis Investigative Site Paris cedex 12 75571 France Details
Novartis Investigative Site Villejuif Cedex 94805 France Details
Novartis Investigative Site Candiolo 10060 Italy Details
Novartis Investigative Site Milano 20162 Italy Details
Novartis Investigative Site Aichi 464-8681 Japan Details
Novartis Investigative Site Chiba 277-8577 Japan Details
Novartis Investigative Site Amsterdam 1066 CX Netherlands Details
Novartis Investigative Site Utrecht 3584 CX Netherlands Details
Novartis Investigative Site Barcelona 08035 Spain Details
Novartis Investigative Site Birmingham B15 2TH United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field